Direct-acting antivirals turned hepatitis C from a lifelong liver disease into a curable infection. They block the specific viral proteins the virus needs to copy itself, and a course of 8 to 12 weeks of tablets clears the virus in over 95% of people — with few side effects, and no interferon injections. It is one of the great therapeutic successes of the last two decades.
Class descriptions are written by the Priya Life Science editorial team. Individual drug pages combine that summary with live label, approval, manufacturer and shortage data from the U.S. FDA via the openFDA API. This page is general information and is not medical advice — it is not exhaustive, drugs within a class are not automatically interchangeable, and approvals and brand names differ between the US, EU/Ireland (EMA/HPRA) and other regions. Always consult the official prescribing information and your clinician or pharmacist. Related: Drug Shortages Tracker · FDA Approvals · All drug comparisons